NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE American · Biotechnology · USD

OS Therapies Incorporated (OSTX) Stock Analysis

OS Therapies Incorporated (OSTX) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.

Last Updated: October 21, 2026

OSTX

$1.27

+$0.01 (+0.79%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare OSTX with… →

OSTX Key Statistics

As of Oct 21, 2026
Trading
Open
$1.27
Previous Close
$1.26
Day's Range
1.25–1.33
52-Week Range
1.15–2.25
Volume
330.13K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.64
Valuation
Market Cap
$59.44M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
3.66
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.08
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$28.75M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
46.81M
1-Year Return
−29.44%
Dividend and dates
Earnings Date
November 16, 2026estimated
Avg Volume
584.82K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, OSTX closed at $1.27, −29.44% over 1 year.

OS Therapies Incorporated (OSTX) has a market capitalization of $59.44M.

In fiscal 2025, OSTX reported revenue of $0.00.

OSTX Stock Return by Calendar Year

OS Therapies Incorporated (OSTX) return since Aug 2024: what $10,000 became

1 year
$10,000 $7,056
−29.44%
Since Aug 2024
$10,000 $5,060
−49.40%

If you had invested $10,000 in OS Therapies Incorporated (OSTX) at the close on August 1, 2024, the earliest close on record here, it would have been worth $5,060 at the close on October 21, 2026: −49.40% in total, −26.42% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−9.29%
2025−67.29%
2024 (partial year)+70.52%

As of October 21, 2026.

OSTX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$28.75M—
2024$0.00−$8.88M—
2023$0.00−$7.79M—
2022$0.00−$6.25M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$28.71M−$28.75M—
2024$0.00—−$6.81M−$8.88M—
2023$0.00—−$4.34M−$7.79M—
2022$0.00—−$4.45M−$6.25M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Analysis

Data-derived

Company Overview

The market values OS Therapies Incorporated (OSTX) at $59.44M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 4 employees.

Over the past 52 weeks the price has ranged from $1.15 to $2.25. OSTX last closed at $1.27 on October 21, 2026. That is +$0.01 (+0.79%) against the previous close. The latest close sits 10.43% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $28.75M. Earnings per share on a trailing basis come to −1.08.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The forward P/E on file is 3.66.

The trailing one-year total return is −29.44%. The stored price history starts on August 1, 2024, and the total return since then is −49.40%. Beta against the wider market is reported at −0.64. Daily returns over the trailing 2 years annualize to a volatility of 104.35%.

Growth & Income

The record shows no dividend for OSTX.

The record holds one complete calendar year, 2025, which returned −67.29%. So far in 2026 the total return is −9.29%.

Peer Comparison

OS Therapies Incorporated (OSTX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
OS Therapies Incorporated OSTX $59.44M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. OS Therapies Incorporated has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About OS Therapies Incorporated

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and is based in Grasonville, Maryland.

Visit website →